Investigation of adenosine endogenous increase decurrent of D-Frutose-1,6-difosfato administration, a glycolytic intermediate. / Investigação do aumento endógeno de adenosina decorrente da administração do intermediário glicolítico D-Frutose-1,6-difosfato

AUTOR(ES)

Daniel Augusto Rodrigues Valerio

DATA DE PUBLICAÇÃO

2009

RESUMO

D-Fructose-1,6-bisphosphate (F1,6BP), a high-energy glycolytic pathway intermediate, is reported to have a many pharmacologically effect, but its underlying mechanism of action in inflammation is incompletely understood. In this study, the aim was to examine the function of F1,6BP on cytokines and adenosine. Then, the possible F1,6BP anti-inflammatory activities in different models of inflammation and its mechanism of action in mice were addressed focusing inhibition of cytokine production or adenosine production enhancement. Mechanical hypernociception (decrease in the nociceptive threshold of animals) was evaluated by the electronic pressure meter test in mice, the myeloperoxidase (MPO) kineticcolorimetric assay was used to evaluate the leukocyte migration to the subcutaneous plantar tissue of mice hind paw, and mice motor performance were evaluated on the rota-rod test. The cytokines levels were measured by ELISA. Adenosine levels were determined by high performance liquid chromatography and this experimental procedure was validated according to ANVISA for this purpose. The pretreatment of mice with F1,6BP reduced the hypernociception induced by intraplantar injection of carrageenan (45%), TNF (40%), IL-1 (46%), KC (33%), prostaglandin E2 (41%) and dopamine (55%). However, FBP treatment did not alter carrageenin-induced cytokines (TNF-, IL-1 and KC) production or the leukocyte migration to the subcutaneous plantar tissue of mice hind paw. On the other hand, the antinociceptive effect of F1,6BP was prevented by systemic and local treatment with an adenosine A1 receptor antagonist (DPCPX) and adenosine treatment presented similar effect of F1,6BP, suggesting that F1,6BP effect is mediated by peripheral adenosine acting on A1 receptors. In agreement, the present work determined by high performance liquid chromatography that D-Fructose-1,6-bisphosphate administration increased the adenosine endogenous levels in the mice plasma. Therefore, F1,6BP mechanism of action seems dependent on adenosine production but not on modulation of hypernociceptive cytokine production. In turn, adenosine acts peripherally on A1 receptor inhibiting hypernociception. The pharmacological evidence that adenosine through activation of adenosine A1 receptor mediates the antinociceptive action of F1,6BP was supported by the finding that in vivo administration of F1,6BP increases the levels of adenosine in the blood samples. Thus, suggesting the treatment with F1,6BP as a possible therapeutic approach to reduce inflammatory pain.

ASSUNTO(S)

adenosine 6-bisphosphate dpcpx. d-fructose-1 adenosina 6-difosfato d-frutose-1 dor citocinas pain cytokine cromatografia líquida de alta eficiência.

Documentos Relacionados

• Construção, avaliação e aplicação de biossensou para frutose utilizando a enzima D-frutose dehidrogenase
• Uso da frutose-1,6-bisfosfato como alternativa paro o isolamento de ilhotas pancreáticas
• N-acetilcisteína e frutose-1,6-bisfosfato: efeito imunomodulador em cultura de células mononucleares
• Efeito da frutose-1,6-bisfosfato sobre as alterações renais associadas à pancreatite aguda experimental
• Vitamin D-influenced gene expression via a ligand-independent, receptor-DNA complex intermediate.